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Abstract 
Background – PTSD is a chronic and debilitating mental illness with limited available 
treatments. New medications, including Angiotensin Type 1 Receptor inhibitors, have been 
found to improve extinction learning retention in rodents and could be a means of improving the 
efficacy of exposure and cognitive based therapies for PTSD and other anxiety related disorders. 
Studies of new medications use an ideal model of extinction that does not mirror the 
inconsistencies of human therapy and recovery. The present experiment attempted to model the 
inconsistent nature of exposure therapy and examine whether the AT1R inhibitor, losartan, 
would still improve extinction learning. 
Methods – Using the fear-potentiated startle paradigm as an extinction paradigm, the study 
investigated whether acute treatment with losartan, an angiotensin type 1 receptor inhibitor, 
could still augment extinction retention. Following Pavlovian fear conditioning, an animal model 
for PTSD, subjects were treated to losartan and tested for extinction learning over the course of 
two days. 
Results – Groups treated with losartan showed consistent significant fear-potentiated startle in 
both tests following initial fear conditioning. In contrast, groups treated with saline did not show 
significant changes in fear-potentiated startle or trend towards a significant increase in startle 
reactivity on either day. 
Conclusions – The significant increase exhibited by the group treated with losartan could be an 
implication that losartan could augment fear memory as well as extinction retention, but further 
study will be necessary to confirm whether the Fear-Potentiated Startle paradigm can truly 
demonstrate fear extinction in animals.  
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Introduction 
 
Post-traumatic Stress Disorder (PTSD) is an often chronic and debilitating mental illness 
that impacts thousands of individuals across the country. According to the most recent 
Diagnostic and Statistical Manual of Mental Health Disorders (DSM V), an individual may 
develop PTSD after exposure to some type of severe trauma such as “actual or threatened death, 
serious injury, or sexual violence.” While most individuals will exhibit acute symptoms of 
distress, such as a negative emotional state, intrusive thoughts or dreams, and hypervigilance, 
these symptoms commonly resolve over a few weeks (Lancaster, Teeters, Gros, & Back, 2016; 
DSM V, 2013). For individuals who suffer from PTSD, symptoms take a significantly longer 
period to resolve. They also may show more severe and debilitating symptoms such as 
dissociative reactions, prolonged psychological distress or physiological reactions to internal or 
external cues related to the trauma, and inability to remember key aspects of the traumatic event 
for a period that exceeds at least one month (DSM V, 2013). For many individuals, this disorder 
can severely lower quality of life by impacting the ability to concentrate on work and personal 
interests, take pleasure in previously enjoyed activities, or form meaningful relationships (Gold, 
Douglas, Thomas, Elliott, Rao, & Miaskowski, 2012; Kearney & Simpson, 2014). 
 Importantly, PTSD is also one of the more common mental health disorders in the United 
States with an estimated 8.3% lifetime prevalence in 2013 (Kessler, Petukhova, Sampson, 
Zaslavsky, & Wittchen, 2012; Kilpatrick, Resnick, Milanak, Miller, Keyes, & Friedman, 2013). 
As a result, seeking a greater understanding of PTSD and potential treatments for the disorder is 
vital for individuals who suffer from it.  
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What are the current treatments for PTSD? 
 Currently, the best known treatments for PTSD are psychotherapeutic treatments 
including exposure therapy, cognitive processing therapy, and relaxation-based therapies 
(Lancaster et al., 2016; Cusack et al., 2016). Unfortunately, some individuals with PTSD do not 
respond effectively to psychotherapy and further, there is a fairly large proportion of individuals 
who drop out of psychotherapy (Lancaster et al., 2016; Najavits, 2015). A 2016 review estimated 
that dropout rates for the most effective forms of psychotherapy range from 10-38% for 
prolonged exposure therapy and around 20% for cognitive processing therapy (Lancaster et al., 
2016).  
While pharmacotherapy is available for patients with PTSD, there currently is limited 
research and understanding of the benefits that some medications can have. Selective serotonin 
reuptake inhibitors (SSRIs) have been the most heavily studied, being used in the treatment of 
depression and anxiety disorders as well (Davidson et al., 2003). Evidence has shown that 
extended treatment with SSRIs (36+ weeks) can reduce risk of PTSD relapse and may also 
improve response to psychotherapies; however, SSRIs can have significantly delayed impact, or 
be ineffective for some patients (Lancaster et al., 2016, Davidson et al., 2001).  
Instead of targeting specific symptoms of PTSD, some newer research has taken a more 
multi-faceted approach in developing pharmacotherapies. A common theory is that, at its core, 
PTSD is largely tied to an inability to effectively extinguish a fear memory resulting in a 
chronically elevated fear response to stimuli that are associated with a traumatic event (Milad, 
Orr, Lasko, Chang, Rauch, & Pitman, 2008; Milad, et al., 2009). Noting that psychotherapies 
have been highly effective, a number of studies have focused on researching treatments that may 
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assist patients by improving learning retention for therapeutic treatments, or otherwise improve 
responsiveness to psychotherapeutic treatments (Lancaster et al., 2016).  
Medications that can augment extinction learning have recently become particularly 
popular. For example, d-Cycloserine (DCS), an NMDA receptor agonist, has been found to 
improve extinction learning in a number of animal studies (Walker, Ressler, Lu, & Davis, 2002). 
In recent years, human studies have also found treatment with DCS to have a small but 
significant impact on improving patient responses to psychotherapy (Mataix-Cols, et al., 2017). 
The results have been mixed, however. Other studies have found that treatment with DCS may 
sometimes actually worsen symptoms of PTSD, potentially because DCS may augment a trauma 
memory if an exposure therapy session is unsuccessful (Litz, et al., 2012; Reinecke & Harmer, 
2015). In other words, the DCS does not assist the patient in discriminating between safety and 
threat cues in an extinction session (Reinecke, et al., 2018). 
PTSD is a prevalent disorder in the United States, and availability and access to preferred 
forms of psychotherapy are limited for large portions of the population. A fast-acting drug that 
could effectively enhance learning of safety cues without exacerbating trauma memory could 
significantly improve recovery time for individuals who suffer from PTSD. This study examines 
whether an anti-hypertensive drug, losartan, can augment extinction learning, and seeks to 
examine whether this drug may still improve extinction learning in mildly stressful 
environments.  
The Renin-Angiotensin System 
The renin-angiotensin system (RAS) is the body’s primary method of long-term 
regulation of the cardiovascular system and does so primarily through the production of the 
peptide hormone, Angiotensin II (Ang II) (Sparks, Crowley, Gurley, Mirotsou, & Coffman, 
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2014). Ang II interacts with two primary receptors, the Angiotensin Type 1 receptors (AT1R) 
and the Angiotensin Type 2 receptors (AT2R), which are located throughout the body with a 
high concentration in the brain (Unger, Steckelings, & Dzau, 2015; Sparks et al., 2014; DSM V, 
2013). These two receptors are both seven-transmembrane G-protein coupled receptors (GPCRs) 
(Unger et al., 2015). The Ang II interaction with the AT1 receptor causes a signaling cascade 
that results in vasoconstriction, bodily salt retention, and inflammation among other symptoms 
related to hypertension (Unger et al., 2015). As a result, drugs such as AT1R specific angiotensin 
receptor blockers (ARBs), and angiotensin converting enzyme inhibitors (ACE-Is), which block 
the synthesis of Ang II, are often used to target this pathway to treat patients who suffer from 
hypertension and other cardiovascular diseases (Marvar, Goodman, Fuchs, Choi, Banerjee, & 
Ressler, 2014). 
 Importantly, it recently has been found that ARBs not only treat symptoms of 
hypertension but can also cause the long-lasting reversal of negative effects, including fibrosis of 
heart and blood vessels and hypertrophy (Unger et al., 2015). These healing effects have been 
attributed to two primary factors. First, activation of AT1 receptor signaling cascade can result in 
the production of AT1R mRNAs that then code for new AT1 receptors (Unger et al., 2015, 
McKinley et al., 2003). By antagonizing the AT1 receptor, ARBs indirectly inhibit any potential 
increases in AT1R activity (McKinley et al., 2003). The second theory is that inhibiting Ang II 
interaction with the AT1 receptor results in an excess of Ang II in the body that can then interact 
with the AT2 receptor (Unger et al., 2015). The AT2 receptor has been found to counter many 
effects caused by AT1 receptor activation (Unger et al., 2015). Activation of the AT2 receptor 
has been found to induce signaling cascades that result in vasodilation, anti-inflammation, and 
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natriuresis, among other effects including anti-fibrosis and neuroregeneration or protection 
(Unger et al., 2015). 
Neuroprotective Effects of Angiotensin Receptor Blockers 
 AT1 receptors are located in multiple areas of the brain, but importantly are located in 
parts of the limbic system, including the amygdala, and the bed nucleus of the stria terminalis 
(BNST) (McKinley et al., 2003). AT1 receptors are also highly localized in the hypothalamus 
and influence the hypothalamic pituitary adrenal (HPA) axis which could link the receptor’s 
association with fear memory (Marvar et al., 2014; McKinley et al., 2003). The AT2 receptor is 
localized to several areas that do not overlap with the AT1 receptor including the thalamus and 
cerebellum, though in humans, AT1 and AT2 receptors are both localized in the cerebellar cortex 
(Namsolleck, Culman, & Unger, 2015). The primary functions of the cerebellar cortex include 
sensorimotor and vestibular control, it may also play a role in cognition (Schmahmann, 2018)  
 Recent studies have shown that RAS may also play a role in the regulation of stress-
related disorders and neuropathologies. Activation of the AT1 receptor results in inflammation in 
the brain that has been associated with stroke, ischemia, and hypertension (Saavedra, 2012; 
Saavedra, 2004). Additional resulting neuronal damage has been associated with reduced 
cognition, depression, and anxiety (Saavedra, 2012; Saavedra, 2004). Other studies have found 
that acute stress can cause a surge of AT1R mRNA in the paraventricular nucleus of the 
hypothalamus which may result in increased levels of AT1 receptors in the brain thus elevating 
stress responses over time (Dumont, Rafrafi, Laforest, & Drolet, 1999). 
 ARBs appear to mediate these effects. ARBs are selective antagonists for AT1 receptors 
and compete with Ang II for the AT1R binding site. As noted previously, ARBs not only reduce 
symptoms caused by activation of the AT1 receptor, but also result in the reversal of symptoms 
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including pathological neuronal remodeling and cerebrovascular inflammation as a result of 
increased activation of the AT2R (Saavedra, 2004; Unger et al., 2015; Bregonzio, Seltzer, 
Armando, Pavel, & Saavedra, 2008).  
Pre-treatment of animals with the ARB, candesartan, prevented a neuroendocrine 
response to isolation and the development of stress-related ulcers in mice (Saavedra, 2004). In a 
more recent study, a knockdown of the AT1 receptor in the subfornical organ (SFO) of the brain 
in mice was found to significantly decrease Ang II binding to the AT1 receptor, and by proxy 
reduce the production of corticotrophin, a stress hormone associated with the AT1R signaling 
cascade (Krause et al., 2011).  
Treatment with ARBs has been further demonstrated to improve mood and ameliorate the 
progression of Alzheimer’s disease (Saavedra, 2004; Gard, 2004). ARBs from the sartan family 
(i.e., losartan, valsartan, and candesartan) have been found to reduce stress levels by reducing 
corticosterone release (Armando, et al., 2001). They also have been found to relieve depressive 
symptoms by acting as indirect agonists for the AT2 receptor (Diniz, Casarotto, Fred, Biojone, 
Castrén, & Joca, 2018). 
The association of the renin-angiotensin system with symptoms of stress has been 
conducive to examinations of the impacts that ARBs may have on reducing symptoms in 
individuals with PTSD. In 2012, a longitudinal study of 500 hypertensive patients who had also 
suffered from severe trauma was conducted (Khoury, Marvar, Gillespie, Wingo, Schwartz, & 
Bradley, 2012). The patients were receiving a variety of treatments for hypertension, including 
diuretics, beta-blockers, calcium channel blockers, angiotensin converting enzyme inhibitors 
(ACE-I) and ARBs. ACE-Is prevent the production of Ang II, thus indirectly reducing activation 
of the AT1R (Khoury et al., 2012). The study found that a select group of individuals prescribed 
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ACE-Is or ARBs showed reduced symptoms of hyperarousal or intrusive thoughts characteristic 
in PTSD (Khoury et al., 2012). In contrast, patients taking other anti-hypertension medications 
that do not interact with the RAS showed no significant decrease in PTSD symptoms (Khoury et 
al., 2012). This suggested that the reduction of PTSD symptoms was associated with RAS 
neuroregulation (Khoury et al., 2012). 
In an effort to better understand the association of the RAS with PTSD symptoms, 
various animal studies have been conducted to examine the mechanism responsible for its 
anxiolytic effects. It is known that ARBs interact with AT1 receptors both within the 
circumventricular organs of the brain that are unprotected by the blood-brain barrier, as well as 
with AT1 receptors in parts of the brain that are protected by the blood-brain barrier including 
the amygdala and hypothalamus (Saavedra, 2004; McKinley, et al., 2003).  
The study that influenced this thesis was conducted by Marvar et al. (2014) and sought to 
examine whether the ARB, losartan, might impact fear memory or have an impact on learning. 
Marvar et al.’s study utilized a traditional Pavlovian fear conditioning model that has been used 
to model PTSD in animals. This model is used for the ease it provides in assessing fear 
acquisition, expression, inhibition, and extinction learning. To summarize the results of the 
study, treatment with losartan was found to have no impact on the acquisition of fear (Marvar et 
al., 2014). Further, the animals in the study showed no enhanced fear extinction following acute 
administration of losartan fear (Marvar et al., 2014). In an extinction training session 24 hours 
following initial treatment, however, the animals treated with losartan did show enhanced 
retention of fear extinction (Marvar et al., 2014). Given losartan is an anti-hypertensive drug, it is 
important to note that reduced fear expression was not a result of acutely lowered blood pressure. 
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The 10 mg/kg dosage of losartan appeared to have no impact on baseline blood pressure (Marvar 
et al., 2014). 
From these data, it does not appear that losartan impacts fear acquisition or recall of fear 
memory. Instead, these results imply that losartan may improve retention of extinction learning 
(Marvar et al., 2014). Similar to d-Cycloserine, this information implies that losartan could 
potentially be useful as a therapy enhancing drug (Reinecke, et al., 2018; Marvar et al., 2014). 
Assisting patients with PTSD with the extinction of aversive memories could improve the 
efficacy and efficiency of exposure therapy. 
As noted, however, d-Cycloserine has been associated with some adverse effects and may 
worsen a fearful memory by enhancing reconsolidation following an unsuccessful therapy 
session or stressful event (Reinecke, et al., 2018; Reinecke & Harmer, 2015). That said, d-
Cycloserine acts on the glutamatergic system while ARBs interact with the RAS (Tomek, 
Nemirovsky, Olive, & LaCrosse, 2013; Marvar et al., 2014). 
By augmenting the healing effects of AT2 receptors and inhibiting the inflammatory 
effects of the AT1 receptor, the ARBs may influence extinction learning differently than d-
Cycloserine (Reinecke, et al., 2018; Unger et al., 2015). There remains a question as to whether 
losartan may allow individuals to discriminate between safety and threat cues while augmenting 
consolidation of fear extinction (Reinecke, et al., 2018). In some ways, the effects of ARBs have 
already been observed in the Khoury (2012) longitudinal study when the helpful effects of ARBs 
were minimized by the combination of the treated group with participants who were treated with 
ACE-Is and further by the small number of participants diagnosed with PTSD. The purpose of 
this study is to further examine the impact of losartan on extinction learning, utilizing another 
fear extinction paradigm. 
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Fear-Potentiated Startle 
In a classic fear conditioning procedure, a subject receives an aversive, unconditioned 
stimulus (US) such as a shock. This US is immediately preceded by a “conditioned stimulus” 
(CS) such as a bell or light that the subject comes to associate with the unconditioned fear 
stimulus. When the subject is re-exposed to the CS, they will exhibit a fear response even in the 
absence of the US. An extinction paradigm mimics human exposure therapy by repeatedly 
exposing an animal to a feared CS in a safe environment and without the US until the animal no 
longer exhibits fearful behavior to the CS. 
As follow-up research for Marvar (2014), this study examined fear extinction in mice 
using the fear-potentiated startle paradigm. The fear-potentiated startle (FPS) paradigm presents 
an aversive but non-harmful stimulus (i.e., a white noise sound) following a conditioned stimulus 
(i.e., a tone). This procedure is often used to assess whether fear conditioning has been 
successful since potentiated startle only occurs following Pavlovian classical conditioning or 
whether a fear response has been effectively extinguished (Davis, Falls, Campeau, & Kim, 1993; 
Walker et al., 2002). The FPS pathway has been useful in previous studies, because it allows 
researchers to infer a state of fear from a heightened reactivity and unlike freezing behavior, 
which is also often measured to assess a state of learned fear in mice and rats, the startle response 
and its neural mechanism is conserved between animals and humans (Davis, 2006).  
Some studies have shown that in humans, fear-potentiated startle was higher in 
individuals who suffer from PTSD or other anxiety related disorders as opposed to participants 
without anxiety or trauma related disorders when the participants sensed that they were in a 
threatening environment (Morgan III, Grillon, Southwick, Davis, & Charney, 1995; Melzig, 
Weike, Zimmermann, & Hamm, 2007; Dunning & Hajcak, 2015; Norrholm, et al., 2011). From 
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a macro perspective, many individuals suffering from PTSD may be unable to leave the 
environments in which they have experienced trauma or may have experienced trauma that is 
easily triggered by commonplace events (Birrer, Michael, & Munsch, 2007; Priebe, Kleindienst, 
Zimmer, Koudela, Ebner-Priemer, & Bohus, 2013; Kilpatrick et al., 2013). As a result, these 
individuals may frequently find themselves in environments of heightened or potentiated stress. 
Though it has not been used as one previously, the paradigm is described as an extinction 
procedure since the conditioned stimulus is presented without the initial unconditioned stimulus 
(i.e., a footshock). That said, previous research implies that using the FPS paradigm as an 
extinction procedure alone may result in delayed extinction to a conditioned stimulus in 
comparison to regular extinction training (Walker et al., 2002). This delay may be caused by the 
startle stimulus creating a disruption to CS processing or an increase in fear in relation to the CS 
(Walker et al., 2002). Extending this information to the human experience, humans with PTSD 
may frequently find themselves in situations of heightened stress that may coincide with an 
aversive cue as opposed to a safety cue. Thus, the FPS paradigm may be a way to model 
heightened stress experienced by humans in animal studies. 
In many ways, this study mirrors the Marvar (2014) study that hypothesized that animals 
treated with losartan have an enhanced consolidation of memory. This study sought to examine 
whether using an FPS paradigm would result in delayed extinction learning as a result of 
coupling the conditioned stimulus with the non-harmful, but still aversive startle stimulus. This 
research further sought to understand whether fear conditioned animals who were treated with an 
acute dose of losartan and exposed to the FPS paradigm would have an increased retention of 
extinction learning in the second day of treatment in comparison to an untreated group. While the 
FPS paradigm presents a slightly aversive stimulus, it was hypothesized that this would not 
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inhibit the organism’s ability to extinguish a fear response to the conditioned stimulus since 
losartan ameliorates the AT1 receptor induced stress response. 
The study has been divided into two experiments. The first experiment provided 
preliminary evidence necessary to implement the second experiment. Though the experiments 
are largely similar, there are some significant differences in the methods and length of each 
process. 
Experiment 1 
Method 
Subjects 
All mice (N = 8) in the experiment were 3-4 month old wild type C57BL/6J males from Jackson 
Laboratory (Bar Harbor, ME). All procedures were approved by the Institutional Animal Care 
and Use Committee of George Washington University and were in compliance with the National 
Institutes of Health guidelines.  
Drugs 
Losartan (Sigma-Aldrich, catalog no. 61188), a selective AT1 receptor antagonist, was 
administered intraperitoneally (i.p.) at a dose of 10 mg/kg in 0.2 ml of a vehicle of 0.9% isotonic 
sterile saline. Saline was administered during control sessions. The mice received a single dose 
of losartan or saline 40 minutes prior to Fear-Potentiated Startle test 1. 
Habituation and Fear-Potentiated Startle Pretest  
Over the first three days, the mice were exposed and acclimated to a non-restrictive clear acrylic 
cylinder (SR-Lab startle response system, San Diego Instruments) attached to an accelerometer 
that measured mV reactivity. On the first day and second day, subjects were exposed to a 17 min 
baseline reactivity test which consisted of 48 0.5 sec white noise bursts at varying decibel levels: 
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65, 81, 90, 95, 100, 105, 110, and 115 dB and a randomized inter-trial interval (between 0-30 
sec). This information was used to select a dB level (100 dB) that evoked a recognizable startle 
response without causing a ceiling effect. 
On the second day, the animals received a pre-FPS test to measure baseline potentiation to the 
tone conditioning since fear reactivity in mice varies greatly within groups (Falls, 2002). The 
FPS test consisted of 5 min silence and 10 “leader trials” (0.5 sec 100 dB noise burst) to 
acclimate the mice to the chamber and stabilize reactivity. This was followed by 15 tone (30 sec, 
6 kHz, 60 dB) trials that co-terminated with a white noise burst (0.5 sec, 100 dB) and were 
interspersed with 15 noise alone trials (0.5 sec, 100 dB), and 15 no-stimulation trials (30 sec 
silence). No-stimulation trials were used to measure baseline movement within the cylinders. 
Each trial was followed by a 30 sec inter-trial interval. 
Cue Fear Conditioning 
Auditory fear conditioning was performed in conditioning test cages (7″ × 7″D12″H; model 
H10-11M-TC) equipped with overhead cameras and grid shock floors (H10-11M-TC-SF). Test 
cages were enclosed in sound attenuating isolation cubicles (Model H10-24T; Coulbourn 
Instruments, Holliston, MA, United States). Animals were habituated to the chambers in two 20 
min sessions two days prior to fear conditioning protocol and both the saline and losartan groups 
received to the fear conditioning protocol. The protocol consisted of 5 min habituation period 
followed by 5 CS-US pairings: a 30 sec auditory tone (6 kHz, 75 dB) co-terminating with a mild 
footshock (0.5 sec, 0.5 mA). There was a 3 min 30 sec inter-trial interval between each pairing. 
The conditioning chambers were cleaned with 70% ethanol between each trial and the animals 
were returned to their home cages for 24 hours following conditioning. 
Fear-Potentiated Startle Extinction Testing 
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The FPS extinction test was performed using the SR-Lab Startle Response System (San Diego 
Instruments). Animals were placed in non-restrictive acrylic cylinders attached to an 
accelerometer that measured mV reactivity. The FPS protocol used in the pretest was also used 
in both posttests. Mice were injected with losartan or saline 40 min prior to the first FPS test and 
returned to their home cages. The conditioning chambers were cleaned with 70% ethanol 
between each test and the animals were returned to their home cages for 24 hours following FPS 
extinction training. 
Timeline of Behavioral Assessment for Experiment 1
 
Analysis 
The conditioning test cages come equipped with a program to calculate %Freezing in animals. 
Fear conditioning was assessed using data for %Freezing during each 30 sec tone. Fear 
conditioning was then calculated by comparing freezing behavior prior to the initial shock (Pre-
US freezing) to freezing behavior following the initial shock (Post-US freezing). A two-way 
ANOVA with time and drug as factors was used to confirm conditioning and similarity between 
treatment groups.  
Fear-potentiated startle was calculated based on a ratio comparing tone + noise trials to noise 
alone trials using the following formula: Percent fear-potentiated startle (%FPS) = [(tone + noise 
burst − noise burst alone)/noise burst alone] × 100. To determine fear potentiation, the average 
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reactivity in mV was calculated for each animal for each set of trials: [No-stimulation], [noise 
burst alone], and [tone + noise]. Percent FPS was then calculated using the above formula for 
each animal.  
Fear Conditioning was assumed based on a significant increase in FPS from Pretest to Posttest1 
(Falls, 2002). It was assumed that animals returned to baseline and had extinguished to the fear 
cue if there was no significant difference between Pretest and Posttest 2. This assumption was 
based off the data that showed that animals who had received extinction treatment in other 
experiments no longer exhibited FPS when exposed to the CS prior to a startle stimulus. 
(Walker, Ressler, Lu, & Davis, 2002) 
A two-way ANOVA was conducted to analyze the main effects of drug treatment (losartan or 
saline) and time (Pre-FPS, Post-FPS 1, Post-FPS 2). A Paired Sample T-test was performed to 
analyze whether extinction occurred between Post-FPS 1 and Post-FPS 2. 
Experiment 2 
Subjects  
All mice (N = 16) in the experiment were 3-4 month old wild type C57BL/6J males from 
Jackson Laboratory (Bar Harbor, ME). All procedures were approved by the Institutional Animal 
Care and Use Committee of George Washington University and were in compliance with the 
National Institutes of Health guidelines.  
Drugs 
Losartan (Sigma-Aldrich, catalog no. 61188) was administered intraperitoneally (i.p.) at a dose 
of 10 mg/kg in 0.2 ml of a vehicle of 0.9% isotonic sterile saline. Saline was administered to the 
control group. The mice received a single dose of losartan or saline 40 minutes prior to Fear-
Potentiated Startle Test 1. 
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Habituation and Fear-Potentiated Startle Pretest 
For two days, the mice were exposed and acclimated to a non-restrictive clear acrylic cylinder 
(SR-Lab startle response system, San Diego Instruments) attached to an accelerometer that 
measured mV reactivity. On the first day, subjects were exposed to a 17 min baseline reactivity 
test which consisted of 48 05 sec white noise bursts at varying decibel levels: 65, 81, 90, 95, 100, 
105, 110, and 115 dB and a randomized inter-trial interval (between 0-30 sec). This information 
was used to select a dB level (100 dB) that evoked a recognizable startle response without 
causing a ceiling effect. 
On the second day, the animals were received a pre-FPS test to measure baseline potentiation to 
the tone conditioning since fear reactivity in mice varies greatly within groups (Falls, 2002). The 
FPS test consisted of 5 min silence and 10 “leader trials” (0.5 sec 100 dB noise burst) to 
acclimate the mice to the chamber and stabilize reactivity. This was followed by 12 tone (30 sec, 
12 kHz, 60 dB) trials that co-terminated with a white noise burst (0.5 sec, 100 dB) and were 
interspersed with 12 noise alone trials (0.5 sec, 100 dB), and 12 no-stimulation trials (30 sec 
silence). No-stimulation trials were used to measure baseline movement within the cylinders. 
Each trial was followed by a 30 sec inter-trial interval. 
Fear Conditioning 
Auditory fear conditioning was performed using the SR-Lab startle response system (San Diego 
Instruments). A metal shock grid was placed in the non-restrictive clear acrylic cylinders for the 
purpose of fear conditioning. Additionally, the environment was modified to reduce contextual 
conditioning (ammonia cleaner was used instead of alcohol cleaner and colored paper was put 
around the walls). Animals were habituated to the chambers in two 20 min sessions two days 
prior to fear conditioning protocol and both the saline and losartan groups received to the fear 
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conditioning protocol. The protocol consisted of 5 min habituation period followed by 5 CS-US 
pairings: a 30 sec auditory tone (6 kHz, 75 dB) co-terminating with a mild footshock (0.5sec 0.5 
mA). There was a 3 min 30 sec inter-trial interval between each pairing. The conditioning 
chambers were cleaned with ammonia cleaner between each trial and the animals were returned 
to their home cages for 24 hours following conditioning. 
Fear-Potentiated Startle Extinction Training 
The FPS extinction test was performed using the SR-Lab Startle Response System (San Diego 
Instruments). The FPS protocol used in the pretest was also used in both posttests. Mice were 
injected with losartan or saline 40 min prior to the first FPS test and returned to their home 
cages. The conditioning chambers were cleaned with 70% ethanol between each test and the 
animals were returned to their home cages for 24 hours following FPS extinction training. The 
following day, the mice were not injected with losartan or saline and received the second FPS 
test. 
Timeline of Behavioral Assessment for Experiment 2 
 
Analysis 
To analyze fear conditioning in mice in the startle apparatus, a baseline measure of the 
accelerometer was taken. The accelerometer was found to have a baseline measure of 7 mV and 
this information was used to calculate freezing in animals. Freezing was assumed if animals 
presented maximal movement of 7 mV. Percent Freezing was calculated for each time point by 
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averaging movement and dividing by the number of trials for each inter-trial interval (time 
between tones). Fear conditioning was then assessed by comparing freezing behavior prior to the 
initial shock (Pre-US freezing) to freezing behavior following the initial shock (Post-US 
freezing). A two-way ANOVA with time and drug as factors was used to confirm conditioning 
and similarity between treatment groups.  
Again, Fear Conditioning was assumed based on a significant increase in FPS from Pretest to 
Posttest1 (Falls, 2002). It was assumed that animals returned to baseline and had extinguished to 
the fear cue if there was no significant difference between Pretest and Posttest 2. This 
assumption was based on the data that showed that animals who had received extinction 
treatment in other experiments no longer exhibited FPS when exposed to the CS prior to a startle 
stimulus (Walker, Ressler, Lu, & Davis, 2002).  
Mirroring analysis for Experiment 1, fear-potentiated startle was calculated based on a ratio 
comparing tone + noise trials to noise alone trials using the following formula: Percent fear-
potentiated startle (%FPS) = [(tone + noise burst − noise burst alone)/noise burst alone] × 100. 
To determine fear potentiation, the average reactivity in mV was calculated for each animal for 
each set of trials: [No-stimulation], [noise burst alone], and [tone + noise]. Percent FPS was then 
calculated using the above formula for each animal.  
A two-way ANOVA was conducted to analyze the main effects of drug treatment (losartan or 
saline) and time (Pre-FPS, Post-FPS 1, Post-FPS 2). A Paired Sample T-test was performed to 
analyze whether extinction occurred between Post-FPS 1 and Post-FPS 2. 
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Results 
Study 1 
 
 
Fear Conditioning. Testing for fear acquisition was conducted prior to drug exposure and 
animals exhibited normal levels of fear conditioning within the Coulbourn Fear Conditioning 
apparatus. This was measured based on an increase in %freezing to the conditioned stimulus 
(tone) over the course of a 5CS-US test (Figure 1). A two-way ANOVA with drug (losartan or 
saline) and time (pre-US exposure vs post-US exposure) was conducted. As expected, there was 
no significance of drug indicating that there was no difference between groups prior to drug 
treatment. There was a significant main effect of time, F (1,6)=75.729, p < .001, indicating that 
all mice were fear-conditioned to the tone.  
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Figure 1. A significant increase in %Freezing from time-point 1 to time-point 5 is used to 
show that fear conditioning occurred over time. Time-point 0 refers to the 5-minute 
habituation period prior to CS-US conditioning. Each of the following time points 
indicates the Average %Freezing over the course of the 30 second tone (CS). 
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Fear-Potentiated Startle. A two-way ANOVA, including drug (losartan or saline) and time 
(pretest, posttest 1, posttest 2) as factors, was conducted. For these pilot data, there were no 
significant main effects and the interaction was not significant. However, there was a trend for a 
main effect of time, F(2,10) = 2.869, p = .104. This trend reflects higher reactivity during 
posttest 1 and posttest 2 compared with pretest (Figure 2). 
Since there was a trend for an effect of time, post-hoc paired sample T-tests were performed to 
assess whether FPS was exhibited in a specific group. There was no significant difference within 
group comparisons for the saline group. While there was no significant difference within group 
comparisons for the losartan group, there was a trend towards significance from pretest to 
posttest 2. 
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Figure 2. While this figure does not show significance, it was used to show trends between 
groups treated with losartan vs. saline. 
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Study 2 
 
 
Fear Conditioning. In this experiment, testing for fear conditioning was conducted prior to drug 
exposure and animals exhibited normal levels of fear conditioning within the San Diego Labs 
Fear Conditioning apparatus (Figure 3). Conditioning was assessed based on a significant 
increase in %freezing to the conditioned stimulus (tone) over the course of a 5CS-US test. A 
two-way ANOVA with drug (losartan or saline) and time (pre-US exposure vs post-US 
exposure) was conducted. Again, there was no significance of drug interaction. There was a 
significant main effect of time, F (1,14)=122.300, p < .001, indicating that all mice were fear-
conditioned to the tone. 
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Figure 3. This figure shows the average increase in % Freezing over time. Fear was 
acquired over the course of 5 tone-shock (CS-US) pairings and freezing was measured 
over the course of each 30 second tone, prior to the fear stimulus.  
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Fear-Potentiated Startle. A two-way ANOVA, including drug (losartan or saline) and time 
(pretest, posttest 1, posttest 2) as factors, was conducted. For these data, there were a significant 
main effect of time, F(2,28) = 9.346, p = .001. This trend reflects higher reactivity during 
posttest 1 and posttest 2 in comparison with the pretest (Figure 4). There was no main effect of 
drug or of interaction, but there was a trend for interaction (drug*time) (F(2,28)=3.319, p = 
.051).  
Since fear-potentiated startle is assessed based on a significant change in potentiated startle 
reactivity between pretest and posttest and since there was a trend for drug*time interaction, 
post-hoc tests were performed. Data were split based on saline or losartan treatment and a Paired 
Sample T-Test was performed. For saline treatment, there was no significant difference from 
pretest (M=38.14, SD=33.07) and posttest 1 (M=55.5, SD=49.60); t(7) = -1.269, p=.245. There 
was also no significant difference from pretest (M=38.14, SD=33.07) to posttest 2 (M=62.20, 
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Figure 4. The figure shows a significant increase in FPS Response between time point 1 
(Pretest) to time point 2 (Posttest 1) for mice treated with losartan. 
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SD=46.64); t(7) = -1.051, p=.328. However, for losartan treatment, there was a significant 
difference between pretest (M=.5364, SD=27.84) to posttest 1(M=60.87, SD=32.94); t(7) = -
7.452, p<.001, as well as between pretest (M=.5364, SD=27.84) to posttest 2 (M=97.01, 
SD=39.63); t(7) = -5.441, p = .001. These results indicate that animals expressed fear-potentiated 
startle following conditioning and further that drug treatment combined with FPS extinction 
training did not result in a return to baseline startle reactivity. 
Discussion 
 There were two principal goals for this study. The first was to examine whether the 
FPS paradigm resulted in extinction learning, albeit delayed in comparison to the typical 
extinction paradigm. The second goal was to examine whether fear conditioned animals that 
were treated with losartan would exhibit increased retention of extinction learning in comparison 
to an untreated group, in spite of the slightly aversive startle stimulus associated with the CS 
(tone). The idea for this study was derived from human studies that suggest that individuals with 
PTSD may frequently find themselves in environments of heightened stress as well as animal 
studies that have shown that the fear-potentiated startle paradigm may be an extinction paradigm 
that interrupts effective CS processing (Morgan III et al., 1995; DSM V, 2013; Walker et al., 
2002). Based on prior knowledge of the renin-angiotensin system and the interactions of losartan 
with the AT1 and AT2 receptors, it was hypothesized that treatment with losartan would enhance 
extinction learning even in the presence of the startle stimulus associated with the FPS paradigm 
(Marvar et al., 2014; Unger et al., 2015; Khoury et al., 2012; Marinzalda, Pérez, Gargiulo, 
Casarsa, Bregonzio, & Baiardi, 2014). (Falls, 2002) 
 While overall, the scope of these data were too limited to provide conclusive evidence 
for either hypothesis, both experiments produced some interesting findings. Interestingly, 
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counter to the hypothesis concerning losartan, the results from Experiment 1 showed that the 
reactivity to the startle stimulus increased from day 1 to day 2 in mice treated with losartan. In 
comparison, there was not even a trend for significance in change over time for mice who were 
fear conditioned and treated with saline. 
 There were a number of limitations to the interpretation of Experiment 1. To start, the 
data from this study was overall insignificant. This was largely attributed to the small sample 
size. Fear-potentiated startle behavior is extremely variable in mice, and as a result, a larger 
sample size was necessary to validate any trends exhibited in Experiment 1.  
 Experiment 1 was thus used to validate a secondary replication of the study. The 
trends from these data were perceived as implying that losartan might have an effect of 
increasing fear expression in the mice who received extinction training using the FPS paradigm. 
The data also implied that FPS could be used as an extinction study. This was indicated by the 
insignificant but slight decrease in percent-potentiation exhibited by saline treated mice from 
posttest 1-posttest 2 in Figure 2.  
 Experiment 2 mirrored Experiment 1 with a few significant changes. First, Experiment 
2 had a larger group size of eight mice per group. Additionally, the tone was changed from 6-
kHz to 12-kHz based on information that a 12-kHz tone may induce less potentiated fear than the 
6-kHz tone prior to fear conditioning (Falls, 2002). This change was made based on a 
consideration that the startle reactivity of the mice in the pretest in Experiment 1 might have 
exhibited potentiation to the tone prior to fear conditioning resulting in a ceiling effect. Lastly, 
Experiment 2 was shortened since only one hearing test was deemed necessary and since fear 
conditioning was conducted in the startle apparatus. 
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 In spite of the changes, Experiment 2 produced similar results exhibited in Experiment 
1. Importantly, the FPS exhibited by the losartan group between pretest to posttest increased 
significantly. This was expected since a significant increase from pretest to posttest indicated that 
fear conditioning had occurred. Unexpectedly, however, the FPS exhibited by the losartan group 
from pretest to posttest 2 also remained significant. This indicated the extinction learning had not 
occurred.  
 Interestingly, the saline group did not show a significant increase in potentiated startle 
from pretest to posttest 1 and further did not show a significant increase from pretest to posttest 
2. Each fear conditioning session was conducted with mixed groups, so fear conditioning of all 
mice was confirmed. In an effort to confirm that fear potentiation was occurring, data for the 
saline treated animals in Experiment 2 were combined with data from mice in preliminary 
experiments that had been treated to the same protocol up to the implementation of posttest 1. 
The new subject population of 14 mice produced a significant difference between pretest and 
posttest 1 indicating that a larger sample size would have been helpful for this experiment.  
 The small sample size created additional caveats for this study and the results are thus 
inconclusive. To begin, this study could not be used to prove the FPS paradigm was an adequate 
fear extinction paradigm. In order to assess whether the subjects were extinguished to the fear 
cue, it would have been necessary for either the saline or losartan group to show significant 
potentiation within the initial posttest and then return to baseline reactivity levels. Since the 
saline group did not exhibit a significant increase in fear-potentiated startle at any time point, 
neither potentiation or extinction to the CS could be confirmed. Since the losartan group showed 
fear potentiation in both pretest to posttest 1 and in pretest to posttest 2, only a failure to 
extinguish could be confirmed. 
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 In spite of the limitations, these data could still provide some insights for future 
studies. While this FPS paradigm could not be confirmed as an effective method of extinction, it 
is possible that the methods used in this experiment simply needed to be adjusted. For example, 
it may be helpful in future studies to utilize a longer FPS extinction period. This study provided 
the animals with only 15 “extinction” (tone + startle) trials per test. Many classic extinction tests 
are significantly longer, exposing the animals to 30+ tones to ensure full extinction to the CS 
(Marvar et al., 2014; Walker et al., 2002). Further study may find that the FPS paradigm could be 
used as a successful extinction paradigm if further adjustments are made. 
 Alternatively, it is possible that the FPS paradigm used was a successful extinction 
paradigm for the saline group and that the effects of extinction would have been more apparent 
with a larger sample size. Further, the group treated with losartan showed significant potentiation 
on both days and in both experiments even with the small sample sizes. Since the increased 
potentiation was consistent between experiments, these results may be an interesting target for 
future study. It is possible that the startle noise interfered with CS processing and as a result, 
losartan, like d-Cycloserine augmented the fear memory (Reinecke et al., 2015). Following this 
line of thought, this study could provide a few implications concerning losartan’s effect on 
memory. The study published by Marvar et al. (2014) stated that losartan might improve 
extinction learning by improving consolidation of the new memory, but consolidation is the 
initial storage of a new memory. The assumption made by Marvar et al. (2014) suggests that 
losartan may improve consolidation of a new extinction memory that then replaces or 
overpowers the old fear memory.  
 Though this study provided inconclusive results, subjects treated to losartan 
consistently demonstrated an increase in potentiation to the tone following from posttest 1 to 
Seidenberg 
 
 28 
posttest 2, something that did not occur with the saline group. The startle stimulus is not harmful 
to the mice, and so if losartan augments consolidation of extinction memory, it would be 
counterintuitive for the new memory to result in a higher level of potentiated startle as was seen 
in this experiment.   
 Though it should be judged carefully, an alternative suggestion is that losartan might 
augment reconsolidation of memory. Reconsolidation occurs when a memory is retrieved and 
then returned to long term memory (Duvarci & Nader, 2004). It has been found that when a 
memory is retrieved, it reenters a labile state and can be altered or come to be associated with 
other memories (Sierra, et al., 2013; Duvarci & Nader, 2004). It is possible that treatment with 
losartan resulted in reconsolidation of the trauma memory associated with a new memory of the 
general discomfort induced by the startle noise. That said, to assess losartan’s effects on learning 
and memory based on the data in this study requires broad assumptions.  
 In order to draw conclusions about the FPS paradigm as a true extinction model, future 
research would require a larger sample population, as well as a reevaluation for the FPS 
extinction method. For example, aside from elongating animal exposure to the FPS paradigm, it 
might be more effective to have multiple exposure sessions to the paradigm instead of only two 
as was performed in this study. Further, if the FPS paradigm is to be used as a model of the 
imperfect nature of human psychotherapeutic treatment, it may be helpful to include segments 
within the paradigm where the animal is exposed to the fear cue without an accompanying startle 
stimulus, thus modeling successful therapeutic sessions.  
 A number of reevaluations and further tests would be necessary to draw conclusions 
about losartan in relation to the FPS paradigm. It is important to note that the possibility that 
Seidenberg 
 
 29 
losartan may potentiate a stress reaction is counter to much of the known information pertaining 
to the drug.  
 For one, losartan is a common anti-hypertension medication and is not associated with 
side effects of increased levels of stress or anxiety. Additionally, the overarching basis for this 
study ties back to the Khoury 2012 study which found that overall, patients exhibited fewer 
symptoms of distress when taking losartan as a medication. Further, acknowledging that many 
patients take hypertension medications such as losartan on a regular basis, the study conducted 
by Marvar et al. 2014 found that continuous injection of losartan in mice did not impact fear 
learning, but still improved extinction retention following traditional extinction training.  
  In conclusion, further analysis will be necessary to establish whether the FPS paradigm 
can act as a true method for modeling the exposure therapy within the lab. Lastly, regardless of 
the fact that the results were inconclusive, it is undeniable that the group treated with losartan 
exhibited significantly higher levels of fear potentiation in comparison to the saline group. It is 
thus still relevant and necessary to further examine the actions of the ARB and further assess 
whether losartan may be a worthwhile medication for the purpose of augmenting learning 
retention. 
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